top of page

​
 

Cougar Biotechnology (now part of Johnson & Johnson) This annual report, issued the first year Cougar went public, focused on the Phase I clinical trial of what is now marketed as ZYTIGA (abiraterone acetate), a metastatic castration-resistant prostate cancer treatment.  

​

CougarBiotechnology pg 2.jpg
CougarBiotechnology2007AnnualReport.pg.
CougarBiotechnology2007AnnualReport.pg 6
CougarBiotechnology2007AnnualReport.pg 5
bottom of page